

Xarelto® programme at ESC 2008 in Munich, Germany

Date	Event	Speaker	Location	Time
Sept 1 st	Anticoagulant therapy: new perspectives in cardiovascular medicine The current role of anticoagulants in cardiovascular medicine The need for new oral anticoagulants in clinical practice; What can ongoing clinical trials demonstrate?; New anticoagulants in developments clinical perspectives	Christoph Bode, Germany	Oslo- Zone A1	18:30 - 20:00
	Welcome and introduction	Christoph Bode, Germany		18:30 - 18:40
	The current role of anticoagulants in cardiovascular medicine	Raffaele de Caterina, Italy		18:40 - 18:55
	The need for new oral anticoagulants in clinical practice	Elaine Hylek, USA		18:55 - 19:10
	What can ongoing clinical trials demonstrate?	Jonathan Halperin, USA		19:10 - 19:25
	New anticoagulants in development: clinical perspectives	Thomas Lüscher, Switzerland		19:25 - 19:40
	Panel and audience discussion			19:40 - 19:55
	Close	Freek Verheugt, The Netherlands		19:55 - 20:00

Poster Sessions

Date	Event	Speaker	Location
Sept 2 nd	Abstract Number: 81940 The oral, direct factor Xa inhibitor rivaroxaban prevented right ventricular pressure increase and hypertrophy without increasing bleeding in a pulmonary artery hypertension model in rats	Elisabeth Perzborn	Posters Zone B4
Sept 3 rd	Abstract Number: 85236 Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran, but is reduced by the direct factor Xa inhibitor rivaroxaban	Elisabeth Perzborn	Posters Zone B4
Sept 3 rd	Abstract Number: 86450 A meta-analysis of three pivotal studies of rivaroxaban for thromboprophylaxis after orthopaedic surgery: effect on symptomatic venous thromboembolism, all-cause mortality and bleeding	Alexander GC Turpie	Posters Zone B4

Exhibition Times

Saturday, Aug 30th 17:00 – 20:00

Sunday, Aug 31st 09:00 – 18:00

Monday, Sept 1st 09:00 – 18:00

Tuesday, Sept 2nd 09:00 – 18:00